PIP5K1C抗体;PIP5K1C Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A431 cells, hela cells, Primary antibody: P11513(PIP5K1C Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11513(PIP5K1C Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P11513(PIP5K1C Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PIP5K1C antibody is a crucial tool for studying the phosphatidylinositol-4-phosphate 5-kinase type 1 gamma (PIP5K1C), an enzyme encoded by the *PIP5K1C* gene. PIP5K1C belongs to the phosphatidylinositol-4-phosphate 5-kinase family, which catalyzes the phosphorylation of phosphatidylinositol-4-phosphate (PI4P) to generate phosphatidylinositol-4.5-bisphosphate (PIP2). PIP2 is a key lipid secondary messenger regulating membrane dynamics, cytoskeletal organization, and cellular signaling pathways such as receptor trafficking, ion channel modulation, and endocytosis. PIP5K1C is particularly noted for its role in neuronal development, synaptic vesicle recycling, and cancer cell migration.

The antibody is widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect PIP5K1C expression, localization, and post-translational modifications in tissues or cell lines. Researchers employ it to explore PIP5K1C's involvement in diseases, including neurodegenerative disorders (e.g., Alzheimer’s), cancer metastasis, and immune dysfunction. Its specificity is often validated via knockout controls or siRNA-mediated knockdown.

Due to alternative splicing, PIP5K1C has multiple isoforms (e.g., PIP5K1C-90 and PIP5K1C-87), and some antibodies may distinguish between these variants. Understanding PIP5K1C's regulatory mechanisms through such antibodies provides insights into therapeutic targeting of PIP2-mediated pathways in disease contexts.